TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04832958
Drug: 99m-TC-PSMA-I&S
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 99mTc-PSMA-I\&S intravenous injection the day before surgery~* 99mTc-PSMA-I\&S SPECT/CT imaging~* 99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations
Study: NCT06281470
Drug: WS016 Single Dose(12g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS016 12g, to be administered orally as a single dose.
Study: NCT06281470
Drug: WS016 Single Dose(24g)
Normalized name: NEEDLE 24G 1IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS016 24g, to be administered orally as a single dose.
Study: NCT06281470
Drug: WS016 Single Dose(36g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS016 36g, to be administered orally as a single dose.
Study: NCT06281470
Drug: WS016 Single Dose(48g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS016 48g, to be administered orally as a single dose.
Study: NCT06281470
Drug: SAD matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, to be administered orally as a single dose.
Study: NCT06281470
Drug: WS016 Multiple Dose(12g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS016 12g, to be administered orally once daily for a consecutive period of 7 days.
Study: NCT06281470
Drug: WS016 Multiple Dose(24g)
Normalized name: NEEDLE 24G 1IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS016 24g, to be administered orally once daily for a consecutive period of 7 days.
Study: NCT06281470
Drug: WS016 Multiple Dose(48g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS016 48g, to be administered orally once daily for a consecutive period of 7 days.
Study: NCT06281470
Drug: MAD matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, to be administered orally once daily for a consecutive period of 7 days.
Study: NCT05421312
Drug: sampling blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
Study: NCT05421312
Drug: Sampling bone tissue
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
Study: NCT05082779
Drug: CS0159
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06384209
Drug: Antidepressants -Fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: If randomised to the intervention arm, participants will be prescribed the first dose of Fluoxetine 20mg or Sertraline 50mg if breastfeeding. They will receive weekly Friendship Bench sessions as in the control arm. The antidepressants will be tapered on the third study visit to Fluoxetine 40mg or Sertraline 100mg.The next tapering will be done on the sixth study visit. The general nurse will be informed on the treatment response and increase Fluoxetine to 60mg and Sertraline to 150mg in patients of the intervention arm without partial response defined as \<30% improvement in PHQ-9 as compared to baseline.
Study: NCT04934072
Drug: FKS518
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneously by single-use prefilled syringe (PFS)
Study: NCT04669600
Drug: SAR445088 (BIVV020)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection
Study: NCT04897321
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA. Intravenous
Study: NCT05115903
Drug: Standard dose of TNFi
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)
Study: NCT04660747
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants or vitamin K antagonists. Please note that the study is fully observational. The choice of anticoagulant type and duration of treatment are left at the discretion of the treating physicians and patients. No treatment, intervention, or examinations are imposed on patients in the context of this study.
Study: NCT04805541
Drug: Mydriatic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Study: NCT06323525
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
Study: NCT06224673
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ophthalmologic drops given topically to participants for an eye toxicity substudy
Study: NCT05107856
Drug: PRT1419
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT1419 will be administered by intravenous infusion
Study: NCT04570501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered by continuous intravenous (IV) infusion
Study: NCT05929716
Drug: Radiation
Normalized name: Miaderm Radiation Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05472766
Drug: Direct Acting Oral Anticoagulant starting at Day 30
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
Study: NCT05472766
Drug: Direct Acting Oral Anticoagulant starting at Day 90
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
Study: NCT06210750
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06210750
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06210750
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06210750
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT05105464
Drug: SYHA1815
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive SYHA1815 orally.
Study: NCT04804605
Drug: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-151 Cream
Study: NCT06000709
Drug: 6% aqueous phenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL of aqueous phenol will be injected at each target genicular nerve under ultrasound guidance
Study: NCT06000709
Drug: Intraarticular Knee Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection 1.5 mL of 0.9% normal saline outside the knee joint capsule under ultrasound guidance
Study: NCT06000709
Drug: Genicular Nerve Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL of 0.9% normal saline will be injected subcutaneously at each target genicular nerve under ultrasound guidance
Study: NCT05076253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care
Study: NCT05696717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, QD
Study: NCT06396078
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg PO BID x 7 days (in addition to ceftriaxone and metronidazole)
Study: NCT06396078
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1 g PO x 1 dose (in addition to ampicillin and amoxicillin)
Study: NCT06396078
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 250 mg IV q 6 hours x 48 hours followed by erythromycin 333 mg PO TID for an additional 5 days (in addition to ampicillin and amoxicillin)
Study: NCT04711980
Drug: Mudan granule
Normalized name: Sudan III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mudan granule,a traditional Chinese medicine formula,consists of nine Chinese herbs.~Other: Standard medical care.Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study: NCT04711980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granule(Placebo) is in accordance with Mudan granule in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study: NCT05821478
Drug: Lymecyclin and corresponding placebos of the experimental arm
Normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week course of oral lymecycline.
Study: NCT05662111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is given in capsules and are administered orally. During the study, participants will receive placebo in four periods of two weeks during the twelve months of follow-up.
Study: NCT06496282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive placebo for improving sleep quality at lease 30 days in 6 weeks of study
Study: NCT04923659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once
Study: NCT04784520
Drug: HA121-28 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
Study: NCT05079425
Drug: NXC736
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04071821
Drug: Zyrtec tablet 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine HCl 10mg tablet
Study: NCT05079425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04468542
Drug: Superior laryngeal nerve block - Placebo (saline)
Normalized name: ACS22Q55 NERVE BLOCK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-cc injection of saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
Study: NCT04572815
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV and SC
Study: NCT04049591
Drug: Higher Dose UFH
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
Study: NCT04049591
Drug: Lower Dose UFH
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
Study: NCT06014372
Drug: CAPEOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
Study: NCT04404387
Drug: Administration of vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).~The other name of the drug: Ascorbic acid.
Study: NCT04404387
Drug: Administration of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo. Patients (in the control arm) will receive dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C. Placebo will be infused over 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute as per the infusion instructions of vitamin C.
Study: NCT06224049
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy preconditioning will be performed before hNeo-T transfusion.
Study: NCT02431221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04888819
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
Study: NCT04888819
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
Study: NCT05758519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04677959
Drug: Standard of Care Asthma Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
Study: NCT06360250
Drug: Tetanus human immunoglobulin (HTIG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus human immunoglobulin (HTIG)
Study: NCT06360250
Drug: Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There were no active ingredients, and other ingredients were the same
Study: NCT05171348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05646706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study: NCT05488340
Drug: LBP-EC01 0.1 x IV dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
Study: NCT05488340
Drug: LBP-EC01 0.01x IV Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
Study: NCT05488340
Drug: LBP-EC01 IV Infusion Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
Study: NCT05488340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose regimen selected from Part 1 of placebo (Tris buffer).
Study: NCT05488340
Drug: LBP-EC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.
Study: NCT05488340
Drug: TMP/SMX
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
Study: NCT06395727
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: traditional fentanyl dose
Study: NCT04761861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet daily
Study: NCT06385730
Drug: neoadjuvant anti-PD-1
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor (toripalimab) 240mg, day 1，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
Study: NCT06293820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study: NCT05572723
Drug: Remifentanil 2 MG
Normalized name: remifentanil 2 MG
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is an opioid; it has sedative, analgesic, and sympatholytic properties.
Study: NCT05137184
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal Fentanyl
Study: NCT05700097
Drug: Dengzhanxixin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental arms for low, and high dose for the standard protocol
Study: NCT05700097
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control arm for the standard protocol
Study: NCT06078670
Drug: CVL218
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.
Study: NCT04808323
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
Study: NCT04808323
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
Study: NCT06354114
Drug: SYHX2011
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, 260 mg/m\^2
Study: NCT05897151
Drug: Continuous spinal anesthesia
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics.~Norepinephrine starting. dose 0.01 micg/kg/min will be ready for both groups if needed (Mean arterial pressure \< 70 or Mean arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics.
Study: NCT05192356
Drug: CKD-828, D097, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05897151
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: After establishing of ASA monitoring, a wide bore cannula (18 G) will be inserted. Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
Study: NCT03402789
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet daily plus 2 hours of eye patching daily
Study: NCT04930796
Drug: VER-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Study: NCT05236634
Drug: Alpha Blockers
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Study: NCT05236634
Drug: Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Study: NCT04816253
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline irrigation and No other drug placed after extraction
Study: NCT04816253
Drug: Methylprednisolone and Hyaluronic acid
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
Study: NCT05017480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous(SC) injection
Study: NCT05426889
Drug: drug conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient did not receive surgical treatment and chose conservative treatment
Study: NCT06407297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous infusion of Placebo
Study: NCT05627063
Drug: ABSK121-NX
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.
Study: NCT04820972
Drug: Antiplatelet Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: using antiplatelet agents in 3 days after surgery